Skip to Main Content

1,388

Views

0

CrossRef citations to date

0

Altmetric

Oncology

Costs of breast cancer recurrence after initial treatment for HR+, HER2−, high-risk early breast cancer: estimates from SEER-Medicare linked data

Alexandra S. Vitkoa Value, Evidence, and Outcomes (VEO) – Oncology, Eli Lilly and Company, Indianapolis, IN, USAView further author information

,

Pam Martinb Medical Decision Modeling Inc, Indianapolis, IN, USAView further author information

,

Sheng Zhangb Medical Decision Modeling Inc, Indianapolis, IN, USAView further author information

,

Adam Johnstonb Medical Decision Modeling Inc, Indianapolis, IN, USAView further author information

,

Robert Ohsfeldtb Medical Decision Modeling Inc, Indianapolis, IN, USA;c Texas A&M University, College Station, TX, USAView further author information

,

Shen Zhengd TechData Service Company, King of Prussia, PA, USAView further author information

&

Astra M. Liepaa Value, Evidence, and Outcomes (VEO) – Oncology, Eli Lilly and Company, Indianapolis, IN, USACorrespondence[email protected]
View further author information